COMP <GO>
CVS vs GRDN // EV/EBITDA & P/E VALUATION
CVS Health Corporation (NYSE) VS. Guardian Pharmacy Services Inc. (Class A) (NYSE) • 15-METRIC TALLY: CVS 5
— GRDN 7
▲ EV/EBITDA & P/E VALUATION LEADER: CVS
LAST: $90.33 (+0.42%) • MKT CAP: $115.53B
valuation
25.7x
LAST: $40.45 (+0.30%) • MKT CAP: $2.56B
valuation
34.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. GRDN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVS | GRDN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.00% | 20.20% | +24.80 | CVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 37.70% | -35.10 | GRDN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.7x | 34.3x | -8.60 | CVS | /valuation <GO> |
| Free Cash Flow Yield | 6.76% | 3.91% | +2.85 | CVS | /fcf-yield <GO> |
| Operating Margin | 1.20% | 5.00% | -3.80 | GRDN | /operating-margins <GO> |
| Net Profit Margin | 0.40% | 3.40% | -3.00 | GRDN | /net-margins <GO> |
| Revenue Growth (YoY) | 7.80% | 17.90% | -10.10 | GRDN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.94% | 0.00% | +2.94 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.31 | 12.39 | -10.08 | GRDN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 50.6 | -2.77 | GRDN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.7x | 43.8x | +16.90 | GRDN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.53B | $2.56B | $112.97B | CVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVS REV | GRDN REV | CVS GROSS % | GRDN GROSS % | CVS FCF | GRDN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $402.07B | $1.45B | 45.0% | 20.2% | $7.81B | $100.3M |
| FY 2024 | $372.81B | $1.23B | 44.7% | 19.9% | $6.33B | $58.0M |
| FY 2023 | $357.78B | — | — | — | -$2.67B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
GRDN // BETA —